AstraZeneca has claimed its first regulatory approval for oral Factor D inhibitor danicopan, getting a green light in Japan for the drug as Voydeya for the treatment of pa
New data with AstraZeneca’s oral Factor D inhibitor danicopan have built the case for the drug as an add-on to complement C5 antibodies for the treatment of paroxysmal noc
Prospects for AstraZeneca's oral Factor D inhibitor danicopan were looking poor after it failed a phase 2 trial in a rare kidney disease in 2020, but a new readout could reinvigorate the dr
The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from P
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.